市場調查報告書

疾病分析:氣喘 - 市場分析與預測

Disease Analysis: Asthma - Forecast and Market Analysis to 2027

出版商 Datamonitor Healthcare 商品編碼 939969
出版日期 內容資訊 英文 80 Pages
商品交期: 最快1-2個工作天內
價格
疾病分析:氣喘 - 市場分析與預測 Disease Analysis: Asthma - Forecast and Market Analysis to 2027
出版日期: 2020年04月01日內容資訊: 英文 80 Pages
簡介

2018年,全球氣喘的患者數估算為3億4360萬人,至2027年預計將增加到3億6370萬人。

本報告提供全球氣喘市場相關調查分析,疾病的背景,治療,上市藥,開發平台醫藥品,臨床試驗,未來趨勢等相關的系統性資訊。

目錄

概要

疾病的背景

  • 定義
  • 患者的分類

治療

  • 控制型藥物或緩解型藥物
  • 加強療法
  • 緩解型藥物為SABA
  • 控制型藥物為ICS、LABA
  • 也考慮追加治療
  • 重度氣喘的追加治療
  • 新的建議

流行病學

  • 盛行率技術

上市藥

開發平台醫藥品

主要的法規趨勢

  • 英國的NICE
  • 美國的FDA
  • 加拿大
  • 安全性:美國的FDA
  • GSK的Trelegy
  • Novartis

成功的可能性

許可證、資產取得交易

臨床試驗形勢

  • 贊助商:各狀態
  • 贊助商:各階段
  • 最近的趨勢

醫藥品評估模式

市場動態

未來趨勢

共識的預測

最近的趨勢和分析師的見解

今後的主要趨勢

KOL的考察

參考文件

附錄

目錄
Product Code: DMKC0215933

Latest key takeaways

Datamonitor Healthcare estimates that in 2018, there were approximately 343.6 million prevalent cases of asthma in individuals aged up to 44 years worldwide, and forecasts that number to increase to 363.7 million prevalent cases by 2027. GINA guidelines released in 2019 included an important change disrupting a fundamental practice in mild asthma management. The new guidelines state that treatment with a short-acting beta 2 agonist (SABA) alone is no longer recommended for adults and adolescents with asthma. While short-acting bronchodilators may provide symptom relief for patients, they remain at risk for severe exacerbations.

The majority of approved drugs in the asthma space include inhaled small molecules, while several newer approvals show a shift towards development of injectable biologics.

Since its launch as the first fixed-dose combination (FDC) of an inhaled corticosteroid (ICS) and a long-acting beta 2 agonist (LABA), GlaxoSmithKline's Advair has become a well-established gold-standard therapy in asthma. However, generic competition in Europe, and more recently in the US, marks the end of this successful history.

Novartis has ended development of its asthma drug fevipiprant following data which showed that the once-daily pill was not effective.

The convenience of pipeline ICS/LABA/long-acting muscarinic antagonist (LAMA) triple FDC therapies will only marginally increase the overall use of the LAMA drug class as physicians remain skeptical about the role of LAMAs in asthma.

In 2020, key catalysts to anticipate include topline results from Phase III studies for tezepelumab and masitinib.

TABLE OF CONTENTS

OVERVIEW

  • Latest key takeaways

DISEASE BACKGROUND

  • Definition
  • Patient segmentation

TREATMENT

  • Main pharmacological treatments are categorized as controllers or relievers
  • Treatment guidelines recommend step-up therapy
  • Reliever medications have traditionally consisted of SABAs
  • Controller medications are dominated by ICSs and LABAs
  • Concomitant use of additional treatments may be considered
  • Add-on treatment for severe asthma has become highly personalized
  • New recommendations upend decades of routine asthma management

EPIDEMIOLOGY

  • Prevalence methodology

MARKETED DRUGS

PIPELINE

KEY REGULATORY EVENTS

  • England's NICE Says No To Sanofi's Dupixent For Asthma
  • US FDA Orders Singulair Boxed Warning On Neuropsychiatric Events Despite 'Limited' Evidence
  • Canada Explains Studies Needed For Subsequent-Entry Orally Inhaled Products
  • Safety Communications: US FDA Panel Offers Menu Of Options For Singulair's Risks
  • GSK's Trelegy On Track To Be First Triple Inhaled Regimen For Asthma
  • Novartis Primed To Re-Energize Respiratory Business, Rivals Close In

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Alvogen Advances Its Branded Offering Via Agreements
  • AstraZeneca Expands Rights To Kyowa Kirin's Benralizumab

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

DRUG ASSESSMENT MODEL

MARKET DYNAMICS

FUTURE TRENDS

  • High biologic prices will translate to high revenues, despite restricted prescribing
  • The ICS/LABA class will remain dominant by patient share, as first-generation products lose share to follow-on products and* generics
  • Skepticism regarding the role of LAMAs in asthma will blunt uptake of triple therapies

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

  • QAW039 for Asthma (December 16, 2019)
  • Seliforant for Asthma (December 2, 2019)
  • Masitinib for Asthma (November 7, 2019)
  • QAW039 for Asthma (October 22, 2019)
  • QMF149 for Asthma (September 30, 2019)
  • QVM149 for Asthma (September 30, 2019)
  • Trimbow for Asthma (September 30, 2019)
  • Multiple Drugs for Asthma (June 25, 2019)
  • REGN3500 for Asthma (June 21, 2019)
  • QMF149 for Asthma (May 30, 2019)
  • QVM149 for Asthma (May 22, 2019)
  • Trelegy Ellipta for Asthma (May 2, 2019)
  • AZD1419 for Asthma (November 29, 2018)

KEY UPCOMING EVENTS

KEY OPINION LEADER INSIGHTS

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Asthma step up therapy
  • Figure 2: Trends in prevalent cases of asthma, 2018-27
  • Figure 3: Overview of pipeline drugs for asthma in the US
  • Figure 4: Pipeline drugs for asthma, by company
  • Figure 5: Pipeline drugs for asthma, by drug type
  • Figure 6: Pipeline drugs for asthma, by classification
  • Figure 7: Probability of success in the asthma pipeline
  • Figure 8: Clinical trials in asthma
  • Figure 9: Top 10 drugs for clinical trials in asthma
  • Figure 10: Top 10 companies for clinical trials in asthma
  • Figure 11: Trial locations in asthma
  • Figure 12: Asthma trials status
  • Figure 13: Asthma trials sponsors, by phase
  • Figure 14: Datamonitor Healthcare's drug assessment summary for asthma
  • Figure 15: Market dynamics in asthma
  • Figure 16: Future trends in asthma
  • Figure 17: QAW039 for Asthma (December 16, 2019): Phase III - LUSTER 1, Phase III - LUSTER 2
  • Figure 18: Seliforant for Asthma (December 2, 2019): Related Drug - Trial Data
  • Figure 19: Masitinib for Asthma (November 7, 2019): Phase III - AB07015
  • Figure 20: QAW039 for Asthma (October 22, 2019): Phase III - ZEAL-1, Phase III - ZEAL-2
  • Figure 21: QMF149 for Asthma (September 30, 2019): Phase III - PALLADIUM
  • Figure 22: QVM149 for Asthma (September 30, 2019): Phase III - IRIDIUM (w/QMF149)
  • Figure 23: Trimbow for Asthma (September 30, 2019): Phase III - TRIGGER , Phase III - TRIMARAN
  • Figure 24: REGN3500 for Asthma (June 21, 2019): Phase II - w/Dupilumab
  • Figure 25: QMF149 for Asthma (May 30, 2019): Phase III - QUARTZ (vs. MF Twisthaler)
  • Figure 26: QVM149 for Asthma (May 22, 2019): Phase II - vs. Salmeterol/Fluticasone
  • Figure 27: Trelegy Ellipta for Asthma (May 2, 2019): Phase III - CAPTAIN
  • Figure 28: AZD1419 for Asthma (November 29, 2018): Phase IIa - INCONTRO
  • Figure 29: Key upcoming events in asthma

LIST OF TABLES

  • Table 1: Patient severity
  • Table 2: Prevalent cases of asthma, 2018-27
  • Table 3: Marketed drugs for asthma
  • Table 4: Pipeline drugs for asthma
  • Table 5: Historical global sales, by drug ($m), 2014-18
  • Table 6: Forecasted global sales, by drug ($m), 2020-24
  • Table 7: QAW039 for Asthma (December 16, 2019)
  • Table 8: Seliforant for Asthma (December 2, 2019)
  • Table 9: Masitinib for Asthma (November 7, 2019)
  • Table 10: QAW039 for Asthma (October 22, 2019)
  • Table 11: QMF149 for Asthma (September 30, 2019)
  • Table 12: QVM149 for Asthma (September 30, 2019)
  • Table 13: Trimbow for Asthma (September 30, 2019)
  • Table 14: Multiple Drugs for Asthma (June 25, 2019)
  • Table 15: REGN3500 for Asthma (June 21, 2019)
  • Table 16: QMF149 for Asthma (May 30, 2019)
  • Table 17: QVM149 for Asthma (May 22, 2019)
  • Table 18: Trelegy Ellipta for Asthma (May 2, 2019)
  • Table 19: AZD1419 for Asthma (November 29, 2018)